Article
Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe.
All News
Article
Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit.
Article
The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released a new guideline for the management of Kawasaki disease that addresses diagnostic issues relating to Kawasaki disease, the treatment of high-risk patients, and the management of
Article
A recent study has shown that the combination of methotrexate (MTX) plus leflunomide (LEF) yields better disease control in psoriatic arthritis, but may not be as well tolerated as monotherapy with MTX.
Article
Pre-print results of the RECOVERY Trial has shown that when baricitinib (BAR) is given to hospitalized severe COVID-19 patients, it results in significantly less mortality.
Article
A promising therapy aimed at halting and even reversing the pathology underlying osteoarthritis (OA) of the knee failed to show any benefit in a randomized trial.
Dr. John Cush
Tweet
anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/Idlqidy04d https://t.co/su3PI5fSaS
Dr. John Cush
Tweet
CDC reports no cross-reactivity of serologic tests performance between Dengue, Zika and SARS-CoV-2 EIA. Study of febrile patients in Puerto Rico (DENV is endemic) with confirmed SARS-CoV-2, DENV, or Zika Dx. EIA specificity was ≥98% https://t.co/nXEBMuSDZL https://t.co/fa9yOqtxiI
Dr. John Cush
Tweet
Changing to a new biologic or sticking with the old one - a PsA patient chooses
QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas)
https://t.co/VJ5tuLN6ae https://t.co/OrxVBwNUsx
Dr. John Cush
Tweet
Baricitinib’s COVID-19 Efficacy in the RECOVERY Trial
https://t.co/PcQC6sQWyu https://t.co/Dqsq6BneM9
Dr. John Cush
Tweet
Failed Osteoarthritis Pulse Ultrasound Study
https://t.co/6JpiVBOfuV https://t.co/3F4iRVZjUs
Dr. John Cush
Tweet
Single center study of individualized anakinra use in 47 autoinflammatory pts (32kids; 43% MAS; 40% systemic JIA). Off-label use in 38%, higher doses in 21 kids (5-29mg/kg); & 5 given IV anakinra; such doses were well tolerated without major AE. https://t.co/wQgw3YAPKX https://t.co/zL3HfdX4Ns
Dr. John Cush
Tweet
Juvenile CADM: JAMA Case - 6 yoF with 4 yrs of rash on hands, feet, elbows, knees. No Resp to topicals. ROS rare cough & SOB; no weakness. Gottrons over hands, knee. Bx +, ANA+ 1:320, nl enzymes, MSA- See how she was Rx https://t.co/l26Y666JKZ https://t.co/XlzWNKILJU
Dr. John Cush
Tweet
Good review of Diagnosis and Treatment of Pulmonary Sarcoidosis in JAMA.
- Lung progression (in only 10%) assoc w/ 12-18% 5yr mortality
- Sx Sarcoid w/ Lung: start Pred 20 to 40 mg/d for 2 -6 wks
- Steroid sparing w/ MTX, AZA or TNFi https://t.co/ylF8KR47gc https://t.co/VUvjYYC8gG
Dr. John Cush
Tweet
Shared Decision Making in PsA
Changing to a new biologic or sticking with the old one - a PsA patient chooses
QD Clinic is sponsored by https://t.co/4UQlqwujiR
(March 19 & 20, 2022 in Las Colinas, Texas)
https://t.co/Hc7ctWtj7A https://t.co/BAApPkxefc
Dr. John Cush
Tweet
We are excited to announce that Dr. Philip Mease will be joining us at RheumNow Live, leading a presentation and discussion on Axial Psoriatic Arthritis & Fatigue and Central Sensitization.
Join the discussion on March 19-20, on site or virtually!
https://t.co/AIteIEHY9E https://t.co/ybXhIelSgM
Dr. John Cush
Tweet
Gout is common but disproportionately affects certain groups (e.g., the elderly, Pacific Islander, Blacks). Ethnic links to gout were also recently shown to be linked to modifiable behavioral factors that may prove useful in managing gout patients.
https://t.co/uvIuw3zFnq https://t.co/EZomBGQIyt
Dr. John Cush
Tweet
Study of 155 adult patients (PsA 61/AS 94) looked at labs & CV risk factors; found IL-18 elevated in peripheral PsA more than axial PsA & AS. Elevations were higher in PsA pts w/ ischemic heart disease correlated w/ atherogenic index & TG levels https://t.co/PQ3fBi8Qdo https://t.co/mewrcwhi4o
Dr. John Cush
Tweet
Another Kind of COVID Discussion
Another kind of COVID (vaccination) discussion - kindness and respect for the patient
QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas)
https://t.co/XkUkqQ1Vli https://t.co/lrPd6jBMjt
Dr. John Cush
Tweet
Tocilizumab Works Best in Non-Mechanical Ventilated COVID-19 Patients
https://t.co/nUrAikqyPS https://t.co/CfmyB7Wwb6
